Non-Hodgkin's lymphoma in the elderly - Part 1: Overview and treatment of follicular lymphoma

ONCOLOGY

Volumn 21, Issue 9, 2007, Pages 1104-1110

  Morrison, Vicki A ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; FLUDARABINE; IBRITUMOMAB TIUXETAN; IODINE 131; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; VINCRISTINE;

AGING; CANCER CENTER; CANCER STAGING; CLINICAL TRIAL; DISEASE CLASSIFICATION; HISTOLOGY; HUMAN; IMMUNOTHERAPY; NONHODGKIN LYMPHOMA; PATHOPHYSIOLOGY; PROGNOSIS; RADIOIMMUNOTHERAPY; REVIEW;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; GERIATRIC ASSESSMENT; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 34548329728     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-30, 2006.
2. Devesa SS, Fears T: Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 52(suppl 19):5432s-5440s, 1992.
3. Coleman MP, Esteve J, Damiecki P, et al: Trends in cancer incidence and mortality. IARC Sci Publ 121:1-806, 1993.
4. Newton R, Ferlay J, Beral V, et al: The epidemiology of non-Hodgkin's lymphoma: Comparison of nodal and extra-nodal sites. Int J Cancer 72:923-930, 1997.
5. Weisenburger DD: Epidemiology of non-Hodgkin's lymphoma: Recent findings regarding an emerging epidemic. Ann Oncol 5(suppl 1):19-24, 1994.
6. Newell GR, Cabanillas FG, Hagemeister FJ, et al: Incidence of lymphomas in the US classified by the Working Formulation. Cancer 59:857-861, 1987.
7. Rabkin CS, Devesa SS, Zahm SH, et al: Increasing incidence of non-Hodgkin's lymphoma. Semin Hematol 30:286-296, 1993.
8. D'Amore F, Brincker H, Christensen BE, et al: Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. Ann Oncol 3:379-386, 1992.
9. National Cancer Institute: SEER Cancer Statistics Review, 1975-2003. Available at http://seer.cancer.gov/cgi-bin/csr/1975_2003/search.pl. Accessed July 12, 2007.
10. Goss PE: Non-Hodgkin's lymphomas in elderly patients. Leuk Lymphoma 10:147-156, 1993.
11. Martelli M, De Sanctis V, Avvisati G, et al: Current guidelines for the management of aggressive non-Hodgkin's lymphoma. Drugs 53:957-972, 1997.
12. Tirelli U, Zagonel V, Errante D, et al: Treatment of non-Hodgkin's lymphoma in the elderly: An update. Hematol Oncol 16:1-13, 1998.
13. Kennedy BJ: Aging and cancer. J Clin Oncol 6:1903-1911, 1988.
14. Groves FD, Linet MS, Travis LB, et al: Cancer surveillance series: Non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 92:1240-1251, 2000.
15. Berkman B, Rohan B, Sampson S: Myths and biases related to cancer in the elderly. Cancer 74:2004-2008, 1994.
16. Rijke de JM, Schouten LJ, Schouten HC, et al: Age-Specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, the Netherlands. Ann Oncol 7:677-685, 1996.
17. McKenna RJ; Clinical aspects of cancer in the elderly. Treatment decision, treatment choices, and follow-up. Cancer 74:2107-2117, 1994.
18. Jelic S, Milanovic N, Tomasevic Z, et al: Comparison of two non-anthracycline-containing regimens for elderly patients with diffuse large-cell non-Hodgkin' s lymphoma - possible pitfalls in results reporting and interpretation. Neoplasma 46:394-399, 1999.
19. Yancik R: Cancer burden in the aged. A epidemiologic and demographic overview. Cancer 80:1273-1283, 1997.
20. Extermann M, Overcash J, Lyman GH, et al: Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16:1582-1587, 1998.
21. Lichtman SM: Aggressive lymphoma in the elderly. Crit Rev Oncol Hematol 33:119-128, 2000.
22. Peters FPJ, Ten Haaft MA, Schouten HC: Intermediate and high-grade non-Hodgkin's lymphoma in the elderly. Leuk Lymphoma 33:243-252, 1999.
23. Sweetenham JW, Williams CJ: Malignant lymphoma in the elderly. Baillieres Clin Haematol 1:493-511, 1987.
24. Niitsu N: Non-Hodgkin's lymphoma in the elderly. A guide to drug treatment. Drugs Aging 14:447-457, 1999.
25. Blum RH, Carter SK, Agre K: A clinical review of bleomycin - a new antineoplastic agent. Cancer 31:903-913, 1973.
26. Gobbi PG, Cavalli C: Treatment of adult non-Hodgkin's lymphomas. Haematologica 71:321-344, 1986.
27. Bristow MR, Mason JW, Billingham ME, et al: Doxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterisation. Ann Intern Med 88:168-175, 1978.
28. Dixon DO, Neilan B, Jones SE, et al: Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience. J Clin Oncol 4:295-305, 1986.
29. Vose JM, Armitage JO, Weisenburger DD, et al: The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 6:1838-1844, 1988.
30. Ballester OF, Moscinski L, Spiers A, et al: Non-Hodgkin's lymphoma in the older person: A review. J Am Geriatr Soc 41:1245-1254, 1993.
31. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classification of non-Hodgkin's lymphoma. Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982.
32. Carbone A, Volpe R, Gloghini A, et al: Non-Hodgkin's lymphoma in the elderly. Cancer 66:1991-1994, 1990.
33. Tirelli U, Zagonel V, Serraino D, et al: Non-Hodgkin' s lymphomas in 137 patients aged 70 years or older: A retrospective European Organization for Research and Treatment of Cancer Lymphoma Group study. J Clin Oncol 6:1708-1713, 1988.
34. Neilly IJ, Ogston M, Bennett B, et al: High grade non-Hodgkin's lymphoma in the elderly-12 year experience in the Grampian region of Scotland. Hematol Oncol 13:99-106, 1995.
35. Hoerni B, Sotto JJ, Eghbali H, et al: Non-Hodgkin's malignant lymphomas in patients older than 80. Cancer 61:2057-2059, 1988.
36. Elias L: Differences in age and sex distributions among patients with non-Hodgkin's lymphoma. Cancer 43:2540-2546, 1979.
37. Carbone A, Tirelli U, Volpe R, et al: Non-Hodgkin's lymphoma in the elderly. Cancer 57:2185-2189, 1986.
38. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.
39. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999.
40. Carbone PP, Kaplan HS, Musshoff K, et al: Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31:1860-1861, 1971.
41. International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993.
42. Hayward RL, Leonard RCF, Prescott RJ: A critical analysis of prognostic factors for survival in intermediate and high grade non-Hodgkin's lymphoma. Br J Cancer 63:945-952, 1991.
43. Velasquez WS, Jagannath S, Tucker SL, et al: Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. Blood 74:551-557, 1989.
44. Coiffier B, Gisselbrecht C, Vose JM, et al: Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 9:211-219, 1991.
45. Miller TP, Lippman SM, Spier CM, et al: HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. J Clin Invest 82:370-372, 1988.
46. Swan F, Huh Y, Katz R, et al: Beta-2-microglobulin (β2M) and HLA-DR cellular expression in relapsing large cell lymphomas (LCL): Relationship to survival and serum β2M levels (abstract). Blood 76(suppl 1):375a, 1990.
47. Bauer KD, Merkel DE, Winter JN, et al: Prognostic implications of ploidy and proliferative activity in diffuse large cell lymphomas. Cancer Res 46:3173-3178, 1986.
48. Grogan TM, Lippman SM, Spier DM, et al: Independent prognostic significance of nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 71:1157-1160, 1988.
49. Wooldridge TN, Grierson HL, Weisenburger DD, et al: Association of DNA content and proliferative activity with clinical outcome in patients with diffuse mixed cell and large cell non-Hodgkin's lymphoma. Cancer Res 48:6608-6613, 1988.
50. Solal-Celigny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004.
51. Leonard RCF, Hayward RL, Prescott RJ, et al: The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. Ann Oncol 2:655-667, 1991.
52. Soubeyran P, Eghbali H, Bonichon F, et al: Low-grade follicular lymphomas: Analysis of prognosis in a series of 281 patients. Eur J Cancer Clin Oncol 27:1606-1613, 1991.
53. Romaguera JE, McLaughlin P, North L, et al: Multivariate analysis of prognostic factors in stage IV follicular low grade lymphoma: a risk model. J Clin Oncol 9:762-769, 1991.
54. Weisdorf DJ, Andersen JW, Glick JH, et al: Survival after relapse of low-grade non-Hodgkin's lymphoma. Implications for marrow transplantation. J Clin Oncol 10:942-947, 1992.
55. Paryani SB, Hoppe RT, Co RS, et al: Analysis of non-Hodgkin's lymphomas with nodular and unfavourable histologies, stages I and II. Cancer 52:2300-2307, 1983.
56. Rudders RA, Kaddis M, Delellis RA, et al: Nodular non-Hodgkin's lymphoma (NHL): Factors influencing prognosis and indicators for aggressive treatment. Cancer 43:1643-1651, 1979.
57. Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4:1470-1480, 1986.
58. Cabanillas F, Smith T, Bodey GP, et al: Nodular malignant lymphoma: factors affecting complete response rate and survival. Cancer 44:1983-1989, 1979.
59. McLaughlin P, Fuller LM, Velasquez WS, et al: Stage I-II follicular lymphoma. Treatment results for 76 patients. Cancer 58:1596-1602, 1986.
60. O'Reilly S, Connors JM, Macpherson N, et al: Malignant lymphomas in the elderly. Clin Geriatr Med 13:251-263, 1997.
61. MacManus MP, Hoppe R: Is radiotherapy curative for stage I and stage II low grade follicular lymphoma? Results of a long term follow-up study of patients treated at Stanford University. J Clin Oncol 14:1282-1290, 1996.
62. Tezcan H, Vose JM, Bast M, et al: Limited stage I and II follicular non-Hodgkin's lymphoma: The Nebraska Lymphoma Study Group experience. Leuk Lymphoma 34:273-285, 1999.
63. Advani R, Rosenberg SA, Horning SJ: Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy. J Clin Oncol 22:1454-1459, 2004.
64. Connors JM, O'Reilly SE: Treatment considerations in the elderly patient with lymphoma. Hematol Oncol Clin North Am 11:949-960, 1997.
65. Peterson BA, Petroni G, Frizzera G, et al: Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: A study of the Cancer and Leukemia Group B. J Clin Oncol 22:5-15, 2003.
66. McLaughlin P, Hagemeister F, Romaguera J, et al: Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol 14:1262-1272, 1996.
67. Maloney DG, Grillo-Lopez AJ, White CA, et al: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997.
68. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998.
69. Feuring-Buske M, Kneba M, Unterhalt M, et al: IDEC-C2B8 (rituximab) anti-CD20 antibody therapy in relapsed advanced-stage follicular lymphomas: Results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 79:493-500, 2000.
70. Hainsworth JD, Litchy S, Burris HA, et al: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20:4261-4267, 2002.
71. Columbat P, Salles G, Brousse N, et al: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 97:101-106, 2001.
72. Witzig TE, Vukov AM, Habermann TM, et al: Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade 1 non-Hodgkin's lymphoma: A phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 23:1103-1108, 2005.
73. Ghielmini M, Schmitz SFH, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response durauion compared with the standard weekly x 4 schedule. Blood 103:4416-4423, 2004.
74. Hainsworth JD, Litchy S, Shaffer DW, et al: Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23:1088-1095, 2005.
75. Czuczman MS, Weaver R, Alkuzweny B, et al: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9 year follow-up. J Clin Oncol 22:4711-4716, 2004.
76. Czuczman MS, Koryzna A, Mohr A, et al: Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 23:694-704, 2005.
77. Forstpointer R, Dreyling M, Repp R, et al: The additon of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of the German Low Grade Lymphoma Study Group (GLSG). Blood 104:3064-3071, 2004.
78. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005.
79. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005.
80. Herold M, Pasold R, Srock S, et al: Results of a prospective randomized open label phase III study comparing rituximab plus mitoxantrone, chlorambucil, prednisolone chemotherapy (R-MCP) to MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma (MCL) (abstract 584). Blood 104:169a, 2004.
81. Salles G, Foussard C, Nicolas M, et al: Rituximab added to aIFN + CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: First analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 atients (abstract 160). Blood 104:49a, 2004.
82. Hochster HS, Weller E, Gascoyne RD, et al: Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood 106:349a, 2005.
83. Hainsworth JD, Litchy S, Morrissey LH, et al: Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23:1500-1506, 2005.
84. Rohatiner AZS, Gregory WM, Peterson B, et al: Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23:2215-2223, 2005.
85. Kaminski MS, Estes J, Zasadny KR, et al: Radioimmunotherapy with iodine (131) tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259-1266, 2000.
86. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002.
87. Kaminski MS, Tuck M, Estes J, et al: 1311-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441-449, 2005.
88. Press OW, Unger JM, Braziel RM, et al: Phase II trial of CHOP chemotherapy followed by tositumomab/iodine-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group protocol S9911. J Clin Oncol 24:4143-4149, 2006.
89. Horning SJ: Low-grade lymphoma 1993: State of the art. Ann Oncol 5(suppl 2):S23-S27, 1994.